The 2023 New England Cannabis Convention, a three-day event being conducted from March 10 – 12, 2023, invites cannabis professionals, investors, entrepreneurs, and growers, for immersive experiences and meaningful interactions.

As the leading cannabis industry event on the east coast, NECANN brings new consumers and relationships to the attendees. The event regularly attracts the largest number of cannabis, MMJ, and hemp industry specialists, and this year will again be the biggest, most significant cannabis industry event on the East Coast!

Home Base for the New England Cannabis Industry

NECANN has been developing appealing conventions for the cannabis industry since 2014, intensifying market opportunities for entrepreneurs, businesses, investors, patients, educators, advocates, and consumers.

This grand Annual Meeting of the East Coast Cannabis Industry features a sold-out exhibit hall including hundreds of businesses spanning the full spectrum of the hemp and cannabis industries. It also embraces five full programming tracks running throughout three days, with several professional speakers covering all the significant news and topics for the New England markets.

The Annual N.E. Cannabis Convention will also honor the key businesses and individuals putting an incredible amount of work into the cannabis industry. The award winners will reveal the best cannabis grown in the northeast. Attendees can leverage numerous separate ticket workshops with incredible networking events and after-parties all weekend.

Who should attend?

Entrepreneurs, cannabis enthusiasts, and the general public can all enjoy the 2023 New England Cannabis Convention, which will offer educational seminars. The informational conferences and panel discussions will provide insights into the cannabis political climate, new/ existing legislation, potential growth, business opportunities, networking and career opportunities, cannabis research, awareness, education, and advocacy.

Cannabis growers and professionals can show you how to nurture your cannabis brand with excellent labelling, representing the newest in vibrant on-demand label media and color printing solutions. Attendees can connect with exhibiting cannabis-related vendors including physicians and doctors, ancillary cannabis product manufacturers, CBD product distributors, local dispensaries and producers, and many others.

Exhibitors will get an opportunity to demonstrate their services and products to a target audience, getting their business noticed while helping to build important collaborative associations with other cannabis business disciplines.

To learn more, please visit https://ibn.fm/Qcc6c

• Miami-based REZYFi Inc., is a mortgage lender that originates traditional loans but strategically is focused on non-traditional markets such as the cannabis industry
• The cannabis industry has enjoyed a boom in market interest but still needs a reliable loan source for real estate mortgages
• REZYFi’s strength as a commercial real estate lender is based on its licensing in the majority of states, with more to come, and in its proprietary automated / machine-learning technology
• Improving national economy trends have reduced pressure on mortgage rates in recent weeks, and many analysts expect that mortgage rates will continue to decrease through the end of the year, increasing the number of loan-seekers in the process

Specialized mortgage loan originator REZYFi provides a critical service to the cannabis industry, which has exploded on the scene in recent years despite the hefty challenges involved in obtaining mortgage loans from federally insured banks reluctant to service an industry legalized only on a state-by-state level.

REZYFi’s model recognizes that income from licensed cannabis operators is legal and sustainable in states such as California, which boasts one of the largest economies in the whole world. The company provides senior loan and project financing optoins to state-licensed operators, with the loans secured by real estate and/or other assets of the borrowers “to the extent permitted by applicable laws and regulations governing such borrowers,” according to REZYFi’s website (https://ibn.fm/yrHRG).

The law of supply and demand means a high degree of competition for the limited properties that may be compliant with municipal regulations. This is key for marijuana businesses in an urban environment where the greatest number of customers are likely to be found. The report notes that the result can be a significant cost challenge for acquiring the real estate. Searching for properties that aren’t a top-grade quality, but which can be improved, or that are off-market in a “green zone” are among potential solutions to help alleviate that situation, it states. REZYFi is set up to deal with these issues.

REZYFi’s corporate strengths — including licensing in most states, with plans to become licensed in all remaining states in the near future, as well as proprietary automated / machine-learning technology that helps drive efficiency — helps clients in the cannabis industry find success. Reduced pressure on mortgage rates coinciding with cooling inflation trends has drawn many property buyers back into the market in recent weeks (https://ibn.fm/n0ic3).

For more information, visit the company’s website at www.REZYFi.com.

NOTE TO INVESTORS: The latest news and updates relating to REZYFi are available in the company’s newsroom at https://ibn.fm/REZY

• Amir Reichman, BiondVax CEO, represented the company at this year’s BIO CEO & Investor Conference held at the Marriott Marquis, New York, on February 6-8
• His presentation focused on the company’s recent successful pre-clinical in vivo results on its innovative inhaled COVID-19 treatment
• Additional results from the study were release in January 2023, indicating that, compared to the control group, hamsters that received the drug one day after infection had negligible SARS-CoV-2 vital titers in their lungs and experienced a significantly milder and shorter illness
• BiondVax’s management is optimistic that its self-administered inhaled NanoAbs will be highly attractive to at-risk people wishing to proactively, effectively, conveniently, and safely protect themselves

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products mainly for treating infectious and autoimmune diseases, took part in the 2023 BIO CEO & Investor Conference held at the Marriott Marquis, New York. The conference, which took place from February 6-8, offered a platform for stakeholders in the biotech industry, bringing together C-Suite leaders and the investor and banking communities for an opportunity to shape the future investment landscape in the biotechnology sector (https://ibn.fm/zLsni).

Amir Reichman, BiondVax’s CEO, represented the company, focusing his presentation on its recent highly successful pre-clinical in vivo results of its innovative inhaled COVID-19 treatment. He also touched on additional pipeline plans for BiondVax, including, but not limited to, nanosized VHH-antibodies (“NanoAbs”) for the treatment of autoimmune diseases such as psoriasis, asthma, psoriatic arthritis, and macular degeneration (https://ibn.fm/RHS4R).

On January 23, 2023, BiondVax announced additional results from its pre-clinical proof-of-concept study of its innovative NanoAb COVID-19 drug. The study intends to mimic a real-world situation in which, for example, at-risk groups, such as the elderly and people with comorbidities, may proactively protect themselves through the company’s self-administered inhaled NanoAb therapy. The results from this research echoed previously reported data from the same study, which indicated that hamsters that received the drug beginning one day after infection had negligible SARS-CoV-2 vital titers in their lungs and experienced milder and shorter illness compared to the control group (https://ibn.fm/XkVIL).

“We continue to be thrilled with the results of this ongoing trial,” noted Mr. Reichman during the announcement of the study’s results.

“There is strong market demand for COVID prophylactics as evidenced by AstraZeneca’s reported Q1 through Q3 2022 EVUSHELD revenues of $1.5 billion. Data from our trial indicate that our NanoAb may effectively serve as both a therapeutic and protective prophylactic drug, which further enhances its value proposition,” he added.

Evusheld was the only remaining FDA approved drug for protection from COVID illness (as opposed to treatment after infection). On January 26, 2023 the FDA pulled their approval of Evusheld because it is not effective against the new dominant COVID variants (https://ibn.fm/nJ3T4). In the pre-clinical proof-of-concept study, BiondVax’s NanoAbs demonstrated efficacy including against all variants of concern. Evusheld and Paxlovid revenues show there’s still huge and likely growing demand for COVID treatments and BiondVax shows very strong potential to fill these needs with a safe, convenient, and effective inhaled NanoAb treatment.

BiondVax’s management is optimistic that its convenient self-administered inhaled NanoAbs will be highly attractive to at-risk people wishing to proactively, effectively, conveniently, and safely protect themselves. With the COVID treatment market posting $100 billion in revenue in 2022, and the figure expected to increase in the new year, BiondVax is positioning itself to take advantage of this growth (https://ibn.fm/XmWTd). Additionally, with the global biologics market expected to post a CAGR of 7.15% from 2022 to 2030, posting a growth of $366.5 billion in 2021 to $719.94 billion in 2030, BiondVax is confident that its current trajectory will not only contribute to but also benefit from this growth.

For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

• SideChannel, a company on a mission to make cybersecurity simple and accessible to company of all sizes, believes that a secure network begins with segmentation, an approach made possible by the offering of vCISOs, together with the application of RealCISO and Enclave technology
• RealCISO allows SideChannel to perform an important initial security audit to identify your organization’s current security posture
• Enclave simplifies microsegmentation – a network security tactic that shrinks your organization’s attack surface

SideChannel (OTCQB: SDCH) believes that all companies should be able to easily, and affordably, understand and manage cyber risk. It also believes that a secure network begins with segmentation, the breaking down of complex tasks into easy-to-understand steps, enhancing productivity and reducing risk. This approach is made possible by the offering of SideChannel’s vCISOs, and the application of Enclave and RealCISO technology.

As a company on a mission to make cybersecurity simple and effective, SideChannel is constantly engaging companies of all sizes, understanding their daily challenges, and creating solutions tailored to these challenges and the clients’ use cases. SideChannel’s flagship offering of their subscription vCISO (virtual CISO) service provides the best in security support for company’s that are not ready for a full-time onsite CISO. To this is added the power of RealCISO and Enclave.

RealCISO is an important tool used by SideChannel CISOs to perform critical initial audits at the beginning of client engagement, offering important insight to a client’s current cybersecurity posture. Its value is in timely identification of security gaps, pointing to short and long-term organizational cybersecurity needs, and providing opportunities to implement critical adjustments (https://ibn.fm/SXw8z).

Enclave simplifies microsegmentation, a network security tactic that shrinks an organization’s attack surface. Enclave, combined with experienced cybersecurity leadership, offers SideChannel clients a more comprehensive cybersecurity solution. This helps ensure faster breach containment, compliance, and network reliability, which yields real savings in unlost productivity (https://ibn.fm/wXn5H).

“Our job is to make cybersecurity simple and accessible,” noted Brian Haugli, SideChannel’s CEO.

“Our focus is to bring real cyber security expertise, solid products, and services, tech-enabled services into the types of companies that usually can’t actually afford full-time resources [and] the right types of resources. So, we’re predominantly focusing on the middle market and startups, and it’s been an underserved market,” he added (https://ibn.fm/yJEh9).

Customer feedback has been integral to SideChannel’s success and the development of its products and services. By having an ear to the ground, the company has managed to create solutions specific to its client base. This has also helped ensure the products’ ability to solve unique customer issues.

The company is committed to growing its consumer base, covering vendors, B2B clients, and more. Its management acknowledges the growing opportunity in this sector, an aspect that will be integral not only to SideChannel’s growth in 2023 but also to its strengthened brand recognition and market positioning.

“I cannot say I have seen anybody else doing what we are doing, which is [exciting]. But we see a lot of other folks out there trying to do something similar, and we are beating them on capabilities and value,” noted Brian.

“So, it tells me that there is an expanding need for this- we are not the only game in town. But it also tells me that we are doing it the way clients are looking for, not just reselling the product or some service out there. We are really bringing a lot of value to our clients, which they recognize,” he added (https://ibn.fm/CqgqK).

For more information, visit the company’s website at www.SideChannel.com.

NOTE TO INVESTORS: The latest news and updates relating to SDCH are available in the company’s newsroom at https://ibn.fm/SDCH

• Coyuchi Inc. is a California-based bed and bath lifestyle brand focused on sustainable practices and producing comfortable, organic products
• The company had a net income of $1.4 million on sales of $33 million last year
• Coyuchi is expanding its product line with two new items sourced from cotton that the company helped grow as part of a collaborative, soil-rejuvenating project last year
• The company launched a Reg A+ investment offering last year and announced that capital raised had topped $1 million by the end of the year
• In a recent podcast interview, the company’s CEO and president outlined Coyuchi’s priorities for expanding its brand in the coming months

Luxury bed, bath and apparel organic product innovator Coyuchi has built its market appeal on a vision of furnishing homes with earth-sustaining, comfortable products for everyday living while keeping its brand similarly fresh as its profile evolves.

“When Coyuchi was founded 30 years ago, the original founder — her goal was to bring organic cotton into the textile industry for home goods, and we’ve really taken that mission to heart and are finding ways to expand on it and continuing to look at the whole process of what we do,” company President and CEO Eileen Mockus said during a recent podcast interview.

“There’s no hall pass for sustainable products. We want what we want, and from my standpoint that’s the most comfortable sheets that you can sleep on, the amazing towel when you get out of the shower that’s absorbent and soft next to your skin,” Mockus told Bell2Bell host Stuart Smith (https://ibn.fm/SpXVN). “Those are the things that we want to incorporate into what you’re buying into when you buy from Coyuchi and, of course, as you invest in Coyuchi.”

All Coyuchi products are created with 100 percent organic fibers and the company demonstrates its commitment to climate-conscious consumers with a traceable supply chain. Coyuchi’s vision includes a production side that will achieve net zero emissions within the next two to three years and net positive emissions by 2030 as part of its earth stewardship mission.

Mockus noted that for two new products that will launch this year, Coyuchi used cotton derived from a collaborative cultivation project on a California farm, using renewable agricultural practices in tandem with the company’s partners in a group called the California Cotton and Climate Coalition (known as C4).

The success of the company’s vision can be seen in some of the customer reviews posted with department store chain Nordstrom’s online site, which has become part of Coyuchi’s supply chain.

“Perfect weight for summer,” one customer wrote about a purpose-crinkled Organic Cotton Percale Sheet set (https://ibn.fm/nvAAu). “these cotton sheets are incredible. I used to only buy high thread count sheets, and even (though) these are not high TC they are amazing with every wash. I live in Fla so used them year round, with layers as needed. Would def be great for summertime in any part of the country.Generally I love this brand and feel good about buying their products. They are mindful about packaging and sustainability… I wish more manufacturers paid mind in these regards.”

Coyuchi is expanding its partnerships with department store retailers, Mockus said.

“We’ll have more of this coming in 2023,” she said. “We’re really interested in partnerships with other retailers. Seventy percent of bedding purchases are made through department stores. We’re an online business and we want to show up with other retailers.”

Investors are welcomed to join with the company’s vision through its Reg A+ offering launched last year, which topped $1 million in capital flow by the end of last year.

“The company is profitable and growing. For the year ended Dec. 31, 2021, the company had net income of $1.4 million on sales of $33 million,” Smith noted.

For more information, visit the company’s website at www.Coyuchi.com.

NOTE TO INVESTORS: The latest news and updates relating to Coyuchi are available in the company’s newsroom at https://ibn.fm/COYU

• A new report projects that the global direct-selling establishments market size will grow from $688.45 billion in 2022 to $763.85 billion in 2023
• SHRG is focused on positioning itself to take advantage of projected growth
• The company has developed opportunities in several spaces, including the health and wellness, travel, and restaurant sectors

In a market forecast to see almost $80 billion growth (https://ibn.fm/7ZJfu), Sharing Services Global (OTCQB: SHRG) is working to offer a variety of options for its brand partners, subscribers and independent sales force. SHRG operates in the direct-selling space, where it is dedicated to developing or acquiring businesses, products and technologies that augment its product and services portfolio and create opportunities for those involved with the company.

“The global direct-selling establishments market size will grow from $688.45 billion in 2022 to $763.85 billion in 2023 at a compound annual growth rate (‘CAGR’) of 11%,” reported the Business Research Company. “The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short-term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global direct-selling establishment’s market size is expected to grow to $1,125.52 billion in 2027 at a CAGR of 10.2%.”

SHRG is focused on positioning itself to take advantage of the growth the sector is projected to experience. The company has developed opportunities in several spaces, including the health and wellness, travel, and restaurant sectors (https://ibn.fm/ExU5C).

As a wholly owned SHRG subsidiary, the Happy Co. operates in the health and wellness industry. The company’s products are marketed primarily through an independent sales force following a direct-selling business model. Currently, the Happy Co. markets and distributes its products in the United States. In addition, the company sells its health and wellness products on a “not-for-resale” basis to consumers in countries outside the U.S.

My Travel Ventures is also a wholly owned subsidiary. As a subscription-based company, My Travel Ventures delivers subscription-based travel services designed to offer the deepest discounts for travel related to airfare, cruises, hotels, resorts, time shares and rental cars. The services are geared for destinations throughout the world and for people of all ages, demographics and economic backgrounds. My Travel Ventures also provides entrepreneurial opportunities to its subscribers by capitalizing on both the direct-selling model and the retail travel business model.

Finally, Sharing Services has entered into an agreement to acquire the exclusive franchise rights in North America to the Hapi Café(TM) brand from Hapi Café Inc. Under the agreement, SHRG will operate directly or through its subsidiaries at least five corporate-owned stores and will also offer licensing rights for others to operate. Each corporate-owned or licensed Hapi Café location will provide customers and brand partners seeking a healthier lifestyle access to functional, healthy food and beverages, a pleasant workspace with free WiFi service, physical fitness, nutrition management, personal workout video content and My Travel Ventures services.

Sharing Services is a publicly traded diversified company dedicated to maximizing shareholder value through the acquisition and development of innovative companies, products and technologies. In addition to its interest in the opportunities mentioned above, the company currently has a controlling interest in MojiLife, which offers a flagship product to scent homes and vehicles that features innovative technology and design (https://ibn.fm/gw2Ko).

For more information, visit the company’s websites at www.SHRGInc.com, www.MyTravelventures.com and www.TheHappyCo.com.

NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• In addition to a recently released shareholder update letter from the company’s CEO, Chris Bunka, Lexaria Bioscience has now released a new investor presentation
• Despite 2022 inflationary conditions, Lexaria has seen growth company-wide – including hitting annual budgets +/- 2% over the last two years
• Lexaria’s patented DehydraTECH(TM) technology offers more effective delivery of active pharmaceutical ingredients into the bloodstream and brain tissue with 28 patents granted and roughly 50 patent applications pending worldwide
• For Q1 2023, Lexaria expects additional results from its hypertension study HYPER-H21-4, dosing completion in its animal dementia study and diabetes study, dosing completion in human nicotine study NIC-H21-1, and submissions and publishing of additional results in research journals
• Lexaria’s anticipated mid-year IND filing would be an important milestone for the company, providing additional interaction with the pharmaceutical industry

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has released its new corporate presentation (https://ir.lexariabioscience.com/presentations). The presentation augments the positive outlook for the coming year put forth in an earlier released shareholder update letter from the company’s CEO, Chris Bunka.

Bunka starts the letter with, “As 2022 came to a close, it isn’t news that nearly all companies – not to mention most people – are facing challenges not experienced in years. Lexaria continues to navigate well and is focused on those things it can control, such as applied R&D designed to entice others to work with us commercially.”

The letter (https://ibn.fm/Yn6uH) shares that despite the some challenging conditions of 2022, Lexaria is forging ahead. It has not terminated staff but is experiencing the opposite, growing its external headcount to numbers higher than it has been in the past. This has allowed the company to conduct and analyze an unprecedented volume of work. Lexaria has managed to grow while exercising excellent fiscal controls, hitting annual budgets +/- 2% for the last two years. Lexaria plans for further growth in 2023 with its patented DehydraTECH(TM) technology.

DehydraTECH is a disruptive drug delivery technology that is more effective at delivering active pharmaceutical ingredients (“APIs”) into the bloodstream and brain tissue. It is applied to multiple ingestible product formats, including tablets, capsules, oral suspensions, mouth melts, and more.

The company has already seen 28 patents granted and roughly 50 patent applications pending worldwide for its DehydraTECH technology (https://ibn.fm/TB2sL). Pharmacokinetic studies have shown the delivery of higher API quantities in less time, including cannabidiol (“CBD”) for hypertension, oral nicotine for reduced risk, and antiviral drugs for COVID-19 and other infectious diseases. An Investigational New Drug (“IND”) enabling program is currently underway for DehydraTECH-CBD as a prospective registered treatment for hypertension with the U.S. Food and Drug Administration (“FDA”).

Pushing forward in 2023, Lexaria’s DehydraTECH drug delivery platform has multiple mainstream applications in cannabinoids, oral nicotine, antivirals, phosphodiesterase inhibitors, and other APIs. This technology increases bioavailability, improves the speed of onset, reduces drug administration costs, and masks unwanted tastes. The company’s pipeline addresses serious unmet patient needs with substantial market potential.

For Q1 2023, Lexaria expects additional results from its hypertension study HYPER-H21-4, dosing completion in its animal dementia study and diabetes study, dosing completion in human nicotine study NIC-H21-1, and submissions and publishing of additional results in research journals. Additionally, during 2023, Lexaria expects to both submit its IND file and commence its IND clinical study – a major step in its maturation as a pharmaceutical company and will be the primary research focus once it begins.

Lexaria believes that if the IND hypertension program is a success, it could potentially pave the way for more commercial pursuits of DehydraTECH-CBD for therapeutic use. This would be a real milestone for the company as an additional way to interact with the pharmaceutical industry.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

Nemaura Medical (NASDAQ: NMRD) is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT(R) and proBEAT(TM). sugarBEAT(R), a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (“CGM”) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT(R) to the U.S. FDA. proBEAT(TM) combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT(R) diabetes program that is currently undergoing pilot studies.

Additionally, Nemaura has launched Miboko, a new metabolic health and well-being program using a non-invasive glucose sensor along with an AI mobile application that helps a user understand how certain foods and lifestyle habits can impact one’s overall metabolic health and well-being. Nemaura believes that up to half the population could benefit from a sensor and program that monitors metabolic health and well-being.

The company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.

To join the 3rd Annual Winter Wonderland Best Ideas Investor Conference, visit https://microcaprodeo.com

About InvestorBrandNetwork’s Virtual Coverage

The InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, provides the online investment community with custom-built portals that include summaries on hundreds of presenting companies. In addition to enabling proficient evaluation of each company via one-click access to market research tools and helpful website links, IBN utilizes social media and syndicated articles to maximize the visibility of various investor conferences.

For more than a decade, IBN has provided real-time coverage for numerous global events and conferences through its various brands, social media accounts and investment newsletters. To further expand visibility of participating companies at these events, and to ensure another successful year for its event collaborations, IBN’s syndication partners have extended digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com

• The modern workplace has undergone a radical shift in recent years, moving increasingly away from an office-centric model towards a more hybrid working environment
• Corporate employees are revealing they are increasingly spending more time in meetings, with over 77% of these taking place online
• Users can host and attend meetings in lifelike virtual reality – with no software downloads – engaging their audiences in a more collaborative and fun way
• In April 2022, the company launched the world’s first web-based, mobile-friendly, audio and video conference platform

Early on Tuesday 8th January 2019, WeWork announced that the company had successfully concluded a $6 billion funding round; the funding exercise – which would ultimately result in the single largest capital raise for a start-up in modern corporate history, valued WeWork at $47 billion on that occasion. At the time, WeWork was heralded as the ultimate disruptor, with Softbank CEO, Masayoshi Son branding the company as possessing a “technology platform that provides a complete solution for space needs” (https://ibn.fm/4bh4D). In-person work was thriving and WeWork had expanded ferociously, broadening its presence to over 425 sites across 27 countries in the nine years since its founding. Less than 14 months later, WeWork’s founder would be ignominiously ousted with the company’s market capitalization written down to a relatively measly $2.9 billion by its lead investor. Whilst WeWork may have symbolized the future of work at its peak in 2019, the global corporate reality in 2023 paints a starkly different picture. A recent study found that on average, professionals were spending over half of their 40-hour workweek in meetings, with 77% of that time spent in an online, videoconferencing environment (https://ibn.fm/ha7Lj) rather than engaging in an in-person meeting as was envisioned only a few years earlier. With employees the world over radically changing their work practices post the recent pandemic, companies are striving to cater to the dramatic shift in corporate and consumer needs; few however have been as impactful as Utopia VR.

Utopia VR is a diversified technology company, pioneering the concept of the ‘Metaverse-As-A-Service’, while centering its focus on the provision of virtual experiences for both businesses and consumer audiences. Launched in April 2022, Utopia VR’s metaverse solution has emerged as the world’s first web-based, mobile-friendly, audio and video conference platform utilizing innovative, 3D, web technology. Users on the platform are enabled to hold Zoom-like, virtual meetings in 3D, or experience those same meetings in lifelike Virtual Reality. Moreover, and uniquely amongst peers, Utopia VR’s metaverse operates across all devices – PC, mobile and virtual reality headsets – whereas many competitors only work in VR or on PC.

When Facebook founder Mark Zuckerberg posted an online image of his very own metaverse-based avatar in mid-2022, he was potentially spelling out the future of the office – a workplace wherein research house, Gartner believes that the metaverse’s “potential to change how individuals and organizations interact with one another and the world around them is so enormous that technology product and service providers already need a strategy” (https://ibn.fm/tZKIY).

In fact, and to that end, data consolidator Statista recently estimated that the global metaverse market size stood at $38.85 billion in 2021, projecting that the industry could soon explode to reach $678.8 billion by 2030, achieving a CAGR of more than 39% over the period. In an even more optimistic scenario, consultancy McKinsey & Company recently forecast that the metaverse could create $5 trillion in opportunity within the same interim of time (https://ibn.fm/pUFOB).

Considering this, Utopia VR’s strategy is clear. The company has sought to revolutionize the work place as we know it, focusing their business model on disrupting the future of enterprise, education and corporate remote solutions. With a management team boasting extensive experience within both, technology and financial markets, an innovative and live product platform and having already started generating revenues, Utopia VR looks well placed to capitalize and pioneer the implementation of the metaverse in the workplace. And unlike Mark Zuckerberg’s initial avatar, the company’s business model seems to have a leg to stand on.

For more information, visit the company’s website at www.UtopiaVR.com.

NOTE TO INVESTORS: The latest news and updates relating to Utopia VR are available in the company’s newsroom at https://ibn.fm/Utopia

• Cannabis businesses continue to face challenges finding opportunities for financing despite the continued drive for legalization
• REZYFi is pivotal providing much-needed support to the cannabis industry through two wholly owned subsidiaries – REZYFi Lending and ResMac Inc.
• For 2023, combined cannabis industry sales are projected to reach $38.8 billion

In recent years, the cannabis industry has seen significant changes – with 39 states legalizing cannabis for medicinal use and 21 states allowing recreational use. For 2023, the combined sales are projected to reach $38.8 billion for the industry (https://ibn.fm/dqo2m). In spite of this significant growth, there is a challenge that cannabis businesses face – access to loans, deposits, and credit cards. Even with Congress’ repeated attempts to pass banking and tax reform for the cannabis industry, there has not been a legislative consensus or enough political will to get it done.

Positioned as one of the first cannabis mortgage bankers in the United States, REZYFi is servicing the needs of both traditional and non-traditional consumers and businesses. The company targets markets that include licensed and permitted cannabis companies, owners of real estate who lease to cannabis companies, and companies and individual homeowners seeking a variety of real estate-related first and additional mortgage-based financing and project-specific financings. Headquartered in Miami, Florida, REZYFi operates through two wholly owned subsidiaries – REZYFi Lending and ResMac Inc.

Through REZYFi Lending, the company leverages a wide network to offer options such as 15- and 30-year fixed-rate loans, FHA loans, VA loans, reverse mortgages, jumbo loans, and adjustable-rate mortgages. REZYFi expects increased funding in marketing and loan agents to drive significant origination growth over the next two years, supported by its planned launch of a high-margin cannabis division.

REZYFi’s second wholly-owned subsidiary, ResMac, has been operating for 13 years. It has closed more than 20,000 loans for more than 15,000 clients. The company expects to accumulate $285 million in retail origination in 2023, alongside $250 million in wholesale origination for the same period. ResMac is further targeting $600 million in origination through its mortgage correspondent operations for 2023.

REZYFi’s diversified approach to the real estate lending sector positions it to capitalize on growth in multiple verticals. The global overall loan servicing market size was valued at $680.8 million in 2021. By 2028, the market is expected to reach $1426.6 million, growing at a CAGR of 11%, growth driven by a rise in demand for offering increased financing for mortgage lenders (https://ibn.fm/VHIQg).

Over the past five years, REZYFi has developed an extensive network of independent mortgage-related brokers and licensed loan officers and believes that this network will be a vital asset moving forward. Using its corporate strengths, REZYFi plans to expand its offering to all states and is currently licensed in 36 states. REZYFi plans to use its seasoned management team, which includes extensive experience in the cannabis and hemp marketplace.

For more information, visit the company’s website at www.REZYFi.com.

NOTE TO INVESTORS: The latest news and updates relating to REZYFi are available in the company’s newsroom at https://ibn.fm/REZY